SI0710479T1 - Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine - Google Patents

Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine

Info

Publication number
SI0710479T1
SI0710479T1 SI9530220T SI9530220T SI0710479T1 SI 0710479 T1 SI0710479 T1 SI 0710479T1 SI 9530220 T SI9530220 T SI 9530220T SI 9530220 T SI9530220 T SI 9530220T SI 0710479 T1 SI0710479 T1 SI 0710479T1
Authority
SI
Slovenia
Prior art keywords
prevention
treatment
combination
receptor antagonist
migraine
Prior art date
Application number
SI9530220T
Other languages
English (en)
Slovenian (sl)
Inventor
Marlene Lois Cohen
Kirk Willis Johnson
Lee Alan Phebus
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SI0710479T1 publication Critical patent/SI0710479T1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI9530220T 1994-10-05 1995-10-03 Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine SI0710479T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/318,391 US5744482A (en) 1994-10-05 1994-10-05 Serotonin agonist in combination with a tachykinin receptor antagonist in the treatment or prevention of migraine
EP95307000A EP0710479B1 (fr) 1994-10-05 1995-10-03 Utilisation d'un agoniste de la sérotonine en combinaison avec un antagoniste du récepteur de la tachykinine pour la fabrication d'un médicament pour la prévention ou le traitement de la migraine

Publications (1)

Publication Number Publication Date
SI0710479T1 true SI0710479T1 (en) 1999-06-30

Family

ID=23237987

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9530220T SI0710479T1 (en) 1994-10-05 1995-10-03 Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine

Country Status (12)

Country Link
US (1) US5744482A (fr)
EP (1) EP0710479B1 (fr)
AT (1) ATE175347T1 (fr)
AU (1) AU4130196A (fr)
DE (1) DE69507112T2 (fr)
DK (1) DK0710479T3 (fr)
ES (1) ES2125567T3 (fr)
GR (1) GR3029666T3 (fr)
IL (1) IL115451A0 (fr)
SI (1) SI0710479T1 (fr)
WO (1) WO1996011000A1 (fr)
ZA (1) ZA958173B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020028798A1 (en) * 1995-12-12 2002-03-07 Omeros Medical Systems Irrigation solution and method for inhibition of pain and inflammation
EP1609477B1 (fr) * 1994-12-12 2011-11-09 Omeros Corporation Solution d'irrigation et utilisation de celle-ci pour inhiber périopérativement la douleur, l'inflammation et/ou les spasmes au niveau d'une structure vasculaire
US7091181B2 (en) 1994-12-12 2006-08-15 Omeros Corporation Method of inhibition of pain and inflammation during surgery comprising administration of soluble TNF receptors
US20040127884A1 (en) * 1994-12-12 2004-07-01 Omeros Corporation Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
AU5966196A (en) * 1995-06-08 1997-01-09 Eli Lilly And Company Methods of treating cold and allergic rhinitis
US6413961B1 (en) 1995-12-12 2002-07-02 Omeros Medical Systems, Inc. Irrigation solution and method for inhibition of pain and inflammation
BR9509985A (pt) 1995-12-12 1998-11-03 Omeros Med Sys Inc Solução para irrigação e método para inibição de dor inflamação e esparmo
AU4074897A (en) * 1996-09-18 1998-04-14 Eli Lilly And Company A method for the prevention of migraine
GB9620777D0 (en) * 1996-10-07 1996-11-20 Merck Sharp & Dohme Therapeutic use
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
DE19917347A1 (de) * 1999-04-16 2000-11-09 Gsf Forschungszentrum Umwelt Verfahren und Vorrichtung zum trockenen Anbringen von Substanzen an inhalierbare pulverförmige Trägerstoffe
JP2001172178A (ja) * 1999-10-25 2001-06-26 Pfizer Prod Inc 偏頭痛治療用のｎｋ−１レセプターアンタゴニスト及びエレトリプタン
AUPQ514600A0 (en) * 2000-01-18 2000-02-10 James Cook University Brain injury treatment
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
WO2003059884A1 (fr) 2001-12-21 2003-07-24 X-Ceptor Therapeutics, Inc. Modulateurs de lxr
US20080213363A1 (en) * 2003-01-23 2008-09-04 Singh Nikhilesh N Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
WO2004112723A2 (fr) 2003-06-20 2004-12-29 Ronald Aung-Din Therapie locale pour le traitement des migraines, des claquages musculaires, des spasmes musculaires, de la spasticite et d'etats apparentes
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20070166336A1 (en) * 2005-12-13 2007-07-19 David Delmarre Stable and palatable oral liquid sumatriptan compositions
WO2009033749A2 (fr) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Utilisation d'un peptide comme agent thérapeutique

Also Published As

Publication number Publication date
AU4130196A (en) 1996-05-02
DK0710479T3 (da) 1999-08-30
ATE175347T1 (de) 1999-01-15
ES2125567T3 (es) 1999-03-01
WO1996011000A1 (fr) 1996-04-18
DE69507112T2 (de) 1999-06-10
ZA958173B (en) 1997-04-01
IL115451A0 (en) 1995-09-28
US5744482A (en) 1998-04-28
GR3029666T3 (en) 1999-06-30
EP0710479B1 (fr) 1999-01-07
EP0710479A1 (fr) 1996-05-08
DE69507112D1 (de) 1999-02-18

Similar Documents

Publication Publication Date Title
GR3029666T3 (en) Use of a serotonin agonist in combination with a tachykinin receptor antagonist for the manufacture of a medicament for the treatment or prevention of migraine
AU2002318211B2 (en) Parenteral administration of 6-hydroxy-oxymorphone for use as an analgesic
DE69734006D1 (de) Verfahren zur erleichterung von schmerzen durch eine kombination von tramadol und einen nmda-antagonist
HUP0104696A2 (hu) 5HT1 receptor agonistákat és metoklopramidot tartalmazó gyógyszerkészítmény migrén kezelésére
EP1186304A3 (fr) Combinations pharmaceutiques pour le traitement d' attaques et de lésions traumatiques du cerveau
CA2305799A1 (fr) Composition de traitement de la dependance a la nicotine contenant un antagoniste du recepteur a la nicotine et medicament antidepresseur ou anxiolytique
AP2002002642A0 (en) A phamaceutical composition for treatment of acute, chronic pain and/ or neuropathic pain and migraines
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
BR0200283A (pt) Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
BR0106462A (pt) Composições farmacêuticas para distúrbios do snc e outros distúrbios
NZ516477A (en) Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
EP1064966A3 (fr) Combinaisons d'agonistes de recepteurs de 5HT 1, de cafeine et d'inhibiteurs de cyclooxygenase-2 pour le traitement de la migraine
BRPI0412430A (pt) polipeptìdeo agonista do receptor de zot e zonulina
WO2001045684A3 (fr) Formulations d'agonistes d'adenosine a1
WO2001045715A3 (fr) Formulations d'agonistes d'adenosine a1
EP0799618A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pur la prévention et au traitment du cancer
PL312198A1 (en) Application of procaine in obtaining a pharmaceutical preparation of analgesic activity with minimum motorial blocking effect
GB9930077D0 (en) Medicaments
CY2499B1 (en) Use of nk-1 receptor antagonists for treating stress disorders.
HK1046847A1 (en) Pharmaceutical combination with analgesic action containing paracetamol and buspirone.
EP1064948A3 (fr) Combinaisons d'agonistes de recepteurs de 5HT 1, de cafeine et d'inhibiteurs de cyclooxygenase-2 pour le traitement de la migraine
WO2001045682A3 (fr) Formulations d'agonistes de l'adenosine a1
EP1508337A3 (fr) Utilisations relatives aux antagonistes et agonistes vis-a-vis du récepteur de la famille Eph pour le traitement des troubles vasculaires